Compare BCHT & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCHT | ALGS |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.9M | 34.6M |
| IPO Year | 2016 | 2020 |
| Metric | BCHT | ALGS |
|---|---|---|
| Price | $0.97 | $1.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $36.88 |
| AVG Volume (30 Days) | 57.5K | ★ 69.7K |
| Earning Date | 11-12-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,626,366.00 | $2,186,000.00 |
| Revenue This Year | $4.39 | $1,433.30 |
| Revenue Next Year | $45.11 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.26 | N/A |
| 52 Week Low | $0.97 | $1.22 |
| 52 Week High | $2.59 | $13.69 |
| Indicator | BCHT | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 33.08 | 16.87 |
| Support Level | N/A | N/A |
| Resistance Level | $1.51 | $7.79 |
| Average True Range (ATR) | 0.13 | 0.52 |
| MACD | -0.00 | -0.26 |
| Stochastic Oscillator | 0.03 | 0.77 |
Birchtech Corp is a provider of specialty activated carbon technologies, delivering solutions for air and water purification. It provides patented and proprietary Sorbent Enhancement Additive (SEA) technologies for mercury emissions capture to the coal-fired utility sector, and is developing water purification technologies with a specialization on forever chemicals such as PFAS and PFOS. Geographically, the company derives all of its revenue from the United States.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.